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LETTERS TO THE EDITOR
Regarding “Screening for abdominal aortic
aneurysm reduces both aneurysm-related
and all-cause mortality”
In a review article by Mastracci and Cinà,1 they stated that the
pooled estimate of the effect of screening on abdominal aortic
aneurysm (AAA)-related mortality showed a relative risk of 0.60
(95% confidence interval [CI], 0.45 to 0.80) in favor of screening
men 65 years of age. The review included four reports of ran-
domized controlled trials (RCTs): the Viborg Country study
(mean 4.3-year follow-up),2 the Western Australia study (median
3.6-year follow-up),3 the Chichester study (men) (mean 10-year
follow-up),4 and the Multicentre Aneurysm Screening Study
(MASS) (mean 4.1-year follow-up).5 Longer follow-up results of
several RCTs, however, have been published to date. Although a
systematic review by Fleming et al6 and our meta-analyses7,8
demonstrated no benefit of screening for all-cause mortality, Mas-
tracci and Cinà1 did not state all-cause mortality. Therefore, we
performed a meta-analysis of currently available longest follow-up
results (both AAA-related and all-cause mortality) of RCTs of
screening for AAA in men.
Our comprehensive search identified four reports (Table): the
Viborg Country study (median 9.6-year follow-up),9 the Western
Australia study (median 3.6-year follow-up),3 the Chichester study
(men) (over 15-year follow-up),10 and the MASS (mean 7.1-year
follow-up).11 Two of the four individual reports demonstrated a
statistically significant benefit of screening over control for AAA-
related mortality. Pooled analysis of the four reports demonstrated
a statistically significant reduction in AAA-related mortality with
screening relative to control in a random-effect model (risk differ-
ence [RD],0.25%; 95% CI,0.46% to0.04%). Two of the four
individual reports demonstrated a statistically significant benefit of
screening over control for all-cause mortality. Pooled analysis of the
four reports demonstrated a statistically significant reduction in all-
cause mortality with screening relative to control in a random-effect
model (RD,1.06%, 95% CI1.81% to0.31%).
In conclusion, the present meta-analysis demonstrated that
screening for AAA significantly reduced not only AAA-related but
also all-cause mortality in men 65 years of age.
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Table. Meta-analyses of outcomes
Viborg Country
study9
Western Australia
study3
Chichester study,
men10 MASS11 Combined
Total participants (No.) 12,639 38,704 6040 6770 125,153
Follow-up (y) 9.6* 3.6* 15 7.1† —
AAA-related mortality (n/N‡ [%])
Screening 14/6333 18/19,352 47/2995 85/33,883 164/62,563
(0.22) (0.09) (1.57) (0.25) (0.26)
Control 51/6306 25/19,352 54/3045 165/33,887 295/62,590
(0.81) (0.13) (1.77) (0.49) (0.47)
RD (95% CI) (%) 0.59 0.04 0.20 0.24 0.25
(0.84 to 0.34) (0.10 to 0.03) (0.85 to 0.44) (0.33 to 0.14) (0.46 to 0.04)
All-cause mortality (n/N‡ [%])
Screening 2184/6333 2232/19,352 2036/2995 6882/33,883 13,334/62,563
(34.49) (11.53) (67.98) (20.31) (21.31)
Control 2234/6306 2571/19,352 2067/3045 7119/33,887 13,991/62,590
(35.43) (13.29) (67.88) (21.01) (22.35)
RD (95% CI) (%) 0.94 1.75 0.10 0.70 1.06
(2.60 to 0.72) (2.41 to 1.10) (2.26 to 2.45) (1.31 to 0.09) (1.81 to 0.31)
MASS, Multicentre Aneurysm Screening Study; AAA, abdominal aortic aneurysm; RD, risk difference; CI, confidence interval.
*Median.
†Mean.
‡Number of deaths/number of participants.
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Reply
We thank Dr Takagi and colleagues for their updated pooled
analysis. Some of the references that they used were not available
when we drafted our manuscript. Their results, however, provide
further evidence to support our call for a National Aneurysm
Screening Programme in Canada.
We believe that “aneurysm-related mortality” is a more sensitive
outcome for interventions (eg, screening) aiming at reducing mortality
from aneurysm rupture. The fact that Dr Takagi and colleagues were also
able todemonstratea reduction inall-causemortality supports thebenefit
of screening programs for this condition.
In three of the references1-3 used by the authors, the difference
between groups in all-cause mortality was largely attributable to
the difference in aneurysm-related death (Table). This confirms
that the randomization process distributes the nonaneurysm-re-
lated deaths equally between the intervention (screening) and the
control groups. The trend in the decrease of all-cause mortality in
the screened population above and beyond the reduction in death
related to abdominal aortic aneurysm may be the effect of a
reduction in lifestyle-related cardiovascular risk factors that are
addressed when the patients access medical care for screening. This
may be an additional benefit of the screening program. However,
because the original studies were not meant or powered to prove
this hypothesis, the issue requires further study.
Tara Mastracci, MD, FRCSC
Claudio S. Cinà, MD, FRCSC, MSc (HRM)
Department of Surgery, Division of Vascular Surgery, McMaster
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Recognition of Air Force surgeons at Wilford Hall
Medical Center-supported 332nd EMDG/Air Force
Theater Hospital, Balad Air Base, Iraq
In the Journal of Vascular Surgery, Peck et al1 reported their
management of vascular trauma in a local population during Op-
eration Iraqi Freedom. Recent experience during the past 30
months in Iraq mandates kudos for Air Force surgeons at Wilford
Hall USAF Medical Center/332nd Hospital in Balad, Iraq, for
their outstanding efforts and accomplishments. This “band of
brothers” has excelled at all aspects of military surgery. They have
observed and documented, presented and published their re-
sults, analyzed their outcomes projecting improvements, per-
formed both basic and clinical research, and registered and
initiated follow-up of their patients. These accomplishments by
relatively few individuals, including graduates and faculty of the
Uniformed Services University of the Health Sciences (USUHS),
is unequaled in the management of combat casualties, including
coalition forces and civilians.
At the 12th Emerging Technologies Course in Hamburg,
Germany, June 11-13, 2007, W. Darrin Clouse, MD, Lt Col,
USAF, MC, reviewed results obtained by him, having just returned
from his most recent deployment to Balad, Iraq, and his col-
leagues. A month prior, members of this team presented their
experience to the European Association for Trauma and Emer-
gency Surgery in Graz, Austria, and the International Congress on
Military Medicine in Tunis, Tunisia. On two occasions in the
previous 2 years, this group has been at the Russian Military
Medical Academy in St Petersburg participating in historic aca-
demic exchanges. These presentations were based on and include
reference to recent publications by the Air Force surgical team and
include four references as examples.2-5
The list of publications of more than 10 exceeds that of any
other known group of surgeons in any war in a similar, relatively
brief period of time. The senior vascular surgeon is Todd E.
Rasmussen, MD, FACS, Lt Col, USAF, MC. Contributing sur-
geons have had varied backgrounds representing a variety of civil-
ian and military training programs. Dr Rasmussen spent 3 years at
Walter Reed Army Medical Center and the USUHS collaborating
with Colonel Sean D. O’Donnell, MC, USA (retired), and with
Colonel David L. Gillespie, MC, USA, who shared the responsi-
bilities for the only vascular fellowship program in the military.
Endovascular procedures were used extensively. Dr Gillespie con-
tinues to serve as the Chief of the Division of Vascular Surgery at
USUHS and provides leadership by example for the Army, work-
ing closely with Major Charles J. Fox, MD, MC, USA.
Finally, with the Base Realignment and Closure Commission
recommendations of 2005, there is integration both in Bethesda,
Maryland, with Walter Reed National Military Medical Center to
include the National Naval Medical Center in association with the
Table. Long-term aneurysm-related, and all-cause mortality in three randomized controlled trials of screening for
abdominal aortic aneurysm
First author Follow-up, years No. Screened Controls
All death AAA-related death All death AAA-related death
Lindholt 1 10 12,639 2184 14 2234 51
Ashton 2 15 6040 2036 47 2067 54
Kim 3 7 67,770 6882 105 7119 196
AAA, Abdominal aortic aneurysm.
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